Functionally, treatment with vismodegib has been shown to increase the number and size of colorectal tumors in mice in colitis-associated models [61,71], while the experimental Hh agonist, SAG21k, which acts at the level of SMO, decreased the colorectal tumor burden [71]. This evidence concerns the gene SMO and colorectal neoplasm.